UPDATE -- ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
26 juin 2018 08h33 HE
|
Achaogen, Inc.
― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ...
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
26 juin 2018 08h00 HE
|
Achaogen, Inc.
― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ...
Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting
11 juin 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting
24 mai 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update
04 mai 2018 07h30 HE
|
Achaogen, Inc.
-- FDA Advisory Committee voted in favor of plazomicin for treatment of adults with complicated urinary tract infections -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO,...
Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections
02 mai 2018 17h12 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Stock Trading Halted Today
02 mai 2018 07h05 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections
26 avr. 2018 08h01 HE
|
Achaogen, Inc.
-- CARB-X funding to support Achaogen’s early-stage aminoglycoside program developing antibiotics for difficult to treat infections that are associated with high mortality -- -- Awarded Up to $2.4...
Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018
25 avr. 2018 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
23 avr. 2018 08h01 HE
|
Achaogen, Inc.
-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif.,...